International Journal of Clinical Research

Objective To evaluate the clinical efficacy of Zuojin Pill in the treatment of bile reflux gastritis (BRG) of liver-stomach heat stagnation type and its effects on related physiological indicators. Methods A total of 66 patients diagnosed with primary BRG of liver-stomach heat stagnation type who were treated at the Department of Spleen, Stomach, Liver and Gallbladder Diseases, Hejiang County Hospital of Traditional Chinese Medicine from January 2023 to June 2024 were enrolled in this study. Using the random number table method, patients were divided into a control group (n = 33) and a treatment group (n = 33). The control group received magaldrate chewable tablets, while the treatment group was administered a combination of magaldrate chewable tablets and Zuojin Pill. Clinical outcomes were compared between the two groups, including overall therapeutic efficacy, changes in traditional Chinese medicine (TCM) syndrome scores before and after treatment, and levels of serum gastrin (GAS), motilin (MTL), and vasoactive intestinal peptide (VIP). Results The total effective rate in the treatment group was significantly higher than that in the control group. The improvement in TCM syndrome scores was more pronounced in the treatment group (P < 0.001). After treatment, the levels of GAS and MTL were significantly higher in the treatment group compared to the control group (P < 0.001), while the VIP level was significantly higher in the control group than in the treatment group (P < 0.001). Conclusion Zuojin Pill, when combined with conventional treatment, can effectively alleviate symptoms in patients with BRG of liver-stomach heat stagnation type, promote gastrointestinal functional recovery, and improve quality of life. The treatment is both safe and effective.

Bile reflux gastritis; Liver stomach stagnation heat type; Gastrin; Gastrodin; Vasoactive intestinal peptide